Xvivo Perfusion ABXVIPF -1.32%91 Cash Ratio is 1.92 as of Mar. 2026, which is 40% below its 10-year median of 3.18. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 843 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 66.9% on this metric.
Xvivo Perfusion AB has a Cash Ratio of 1.92. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Xvivo Perfusion AB's Cash Ratio or its related term are showing as below:
XVIPF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.75 Med: 3.18 Max: 8.34
Current: 1.92
During the past 13 years, Xvivo Perfusion AB's highest Cash Ratio was 8.34. The lowest was 0.75. And the median was 3.18.
XVIPF's Cash Ratio is ranked better than 66.9% of 843
companies
in the Medical Devices & Instruments industry
Industry Median: 0.97
vs XVIPF: 1.92
Xvivo Perfusion AB (OTCPK:XVIPF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Xvivo Perfusion AB Cash Ratio Related Terms
Xvivo Perfusion AB Cash Ratio Historical Data
* Premium members only.
The historical data trend for Xvivo Perfusion AB's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Xvivo Perfusion AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xvivo Perfusion AB (XVIPF) has a Cash Ratio of 1.92 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Xvivo Perfusion AB and its competitors. This is 40% below median its historical median of 3.18. Over the past decade, Xvivo Perfusion AB's Cash Ratio has ranged from 0.75 to 8.34. According to the industry distribution chart, Xvivo Perfusion AB ranks #279 out of 843 companies in the Medical Devices & Instruments industry, placing it in the top 33.1%.
Is Xvivo Perfusion AB's Cash Ratio too high?
Xvivo Perfusion AB's current Cash Ratio of 1.92 is 40% below median its 10-year median of 3.18. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 8.34. The Medical Devices & Instruments industry median Cash Ratio is 0.97. Xvivo Perfusion AB's value of 1.92 is 97.9% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #279 out of 843 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cash Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #279 out of 843 companies for Cash Ratio. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median Cash Ratio is 0.97. Xvivo Perfusion AB's value of 1.92 is 97.9% above this benchmark. Historically, Xvivo Perfusion AB's own Cash Ratio has ranged from 0.75 to 8.34 over the past decade. While the company's 10-year median is 3.18 vs. the industry median of 0.97, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.97, based on 843 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current Cash Ratio of 1.92 is 97.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current Cash Ratio is 1.92, which is 40% below median its own 10-year median of 3.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current Cash Ratio is 1.92, which is 40% below median its 10-year median of 3.18 and 97.9% above the Medical Devices & Instruments industry median of 0.97. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current Cash Ratio is 1.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
Cash Ratio: 1.92 (40% below median its 10-year median of 3.18)
GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
Industry Position: 97.9% above the Medical Devices & Instruments median (#279 of 843)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
